This interactive symposium will enhance knowledge of MASH diagnosis, risk stratification, and treatment. Expert-led sessions will review noninvasive diagnostic tools, guideline-driven staging, lifestyle interventions, and emerging therapies. Case-based discussions will engage learners in applying concepts to clinical scenarios and addressing real-world challenges in the diagnosis and proactive management of MASH.<br />
<br />
Supported by: Novo Nordisk<br />
<br />
Organized by:&nbsp;Med Learning Group&nbsp;<br />
<br />
Link:&nbsp;<a href="https://www.medlearninggroup.com/cme-programming/mash-sympo/">https://w… />
<br />
Important Note: Continuing education credits for Satellite Symposia are offered by the sponsoring organizations. These sessions are not accredited by AASLD.

Presenters in this symposium focus on the varied functions of liver endothelial cells (ECs). ECs are specialized cells increasingly recognized for their heterogeneity and their key role in liver diseases and carcinogenesis. Recent advances in the understanding of EC function were made possible with refined isolation techniques coupled with multiomics studies. Speakers review emerging literature that defines liver ECs beyond their role as vascular barriers to critical mediators in various biological processes under physiologic and pathologic conditions. 

Developed by the Patient Advisory Group, specialists in the cholestatic liver diseases primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) collaborate with patient advocates to shine a light on: (1) newly available treatments for PBC; (2) a new tool for patients to use during their first visit with their hepatologist; (3) an exciting registry for patients with PSC; and (4) what patients need to know about symptom management. 

Join us for a poster highlight of the top abstracts from the Liver Transplantation and Surgery (LT&amp;S) SIG.&nbsp;<br />
&nbsp;

This interactive, joint AASLD and Society on Liver Disease in Africa (SOLDA) community conversation explores the global epidemiology of DILI and regional differences in its etiology. Needs associated with DILI and associated registries are identified. Through case presentations, panelists illustrate unique features of etiologies of DILI in Africa and highlight differences in diagnostic strategies and management. Presenters also review DILI survey data from Africa and identify DILI-related research gaps. The session aims to formulate strategies to overcome DILI managment challenges and advance DILI-related research in Africa.&nbsp;<br />
<br />
&nbsp;

Continuing the successful AASLD-KASL collaboration underway since 2023, this session highlights practice-changing innovations in hepatology from leading researchers in the U.S. and Korea. Topics include the application of artificial intelligence for non-invasive assessment of liver fibrosis in patients with MASLD, the use of speech pattern analysis as a digital biomarker for detecting hepatic encephalopathy, clinical data on autologous bone marrow-derived mesenchymal stem cell transplantation for liver cirrhosis, and AI-powered tools that synthesize clinical guidelines to support real-time decision-making. A panel discussion will follow to explore the clinical impact, implementation challenges, and global relevance of these emerging technologies.

Join us for a poster highlight of the top abstracts from the Pediatric Liver Disorders (PLD) SIG.&nbsp;<br />
&nbsp;

Join us for a poster highlight of the top abstracts from the Liver Fibrosis SIG.&nbsp;<br />
&nbsp;

This session on alcohol-associated liver disease (ALD) provides a comprehensive overview from both patient and physician perspectives, emphasizing early detection, equitable access to treatment, and inclusive research practices. The session includes a patient sharing their experiences, highlighting the physical and emotional challenges of living with ALD and the importance of support systems. Physicians discuss early detection, detailing diagnostic tools and the benefits of early intervention. They also address how disparities influence access to liver transplantation and clinical trial opportunities, and propose strategies that center on equity. After the individual presentations, a panel of speakers answer questions from the audience and engage in a dialogue about the future directions in ALD detection, treatment, and research.